Fluctuations of Epstein-Barr Virus Antibodies and Nasopharyngeal Carcinoma Risk
Author Information
Author(s): Cao Su-Mei, Liu Zhiwei, Jia Wei-Hua, Huang Qi-Hong, Liu Qing, Guo Xiang, Huang Teng-Bo, Ye Weimin, Hong Ming-Huang
Primary Institution: State Key Laboratory of Oncology in Southern China, Sun Yat-sen University, Guangzhou, China
Hypothesis
The study aims to analyze the fluctuations of antibodies against Epstein-Barr virus (EBV) before histopathological diagnosis to assess the risk of nasopharyngeal carcinoma (NPC).
Conclusion
Elevated EBV antibodies, particularly with ascending titers, are strongly associated with an increased risk for nasopharyngeal carcinoma.
Supporting Evidence
- 125 cases of NPC occurred during an average of 16.9 years of follow-up.
- Serological levels of VCA/IgA and EA/IgA were significantly associated with increased risks for NPC.
- Relative risk was highest among participants with ascending titers of EBV VCA/IgA antibodies.
Takeaway
This study found that higher levels of certain antibodies can mean a higher chance of getting a type of throat cancer called nasopharyngeal carcinoma.
Methodology
The study used a population-based screening program with serological tests for EBV antibodies and followed participants for 20 years.
Potential Biases
Potential confounding effects from unmeasured environmental risk factors.
Limitations
The study lacked information on other environmental risk factors and was conducted in a high-risk area, which may limit generalizability.
Participant Demographics
Participants were Cantonese residents of Sihui County, aged 30-59, with no prior history of NPC.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 7.1 to 64.1
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website